



3D Cell Culture Cancer Models: Development and Applications

Guest Editors:

Dr. Loretta L. del Mercato

CNR-Institute of Nanotechnology,
c/o Campus Ecotekne, Via
Monteroni, 73100 Lecce, Italy

loretta.delmercato@
nanotec.cnr.it

Dr. Erika Parasido

Lombardi Comprehensive Cancer
Center, Georgetown University,
Washington, DC 20057, USA

Erika.Parasido@georgetown.edu

Deadline for manuscript
submissions:


31 July 2020

Message from the Guest Editors

Despite the advances in the treatment, cancer is still in the top 10 causes of death worldwide. Therefore, the need of new patient-derived cancer models to improve personalized therapy is critical. Due to their ability to recapitulate the structural and functional aspect of their matched organs, 3D cell culture cancer models have received huge attention from a variety of specialized fields, including cell biology, molecular biology, chemistry, physics, engineering and nanotechnology. This Special Issue aims to bring together scientists and physicians to discuss the state-of-the-art in *in vitro* cancer modeling. The goal is to highlight those approaches that will drive future research in the study of 3D cell culture cancer models for personalized drug sensitivity testing or to study the tumor cell physiology.

Reviews, articles and protocols that explore advanced materials and methods to generate 3D *in vitro* tumor models that mimic the native heterogeneity and the three-dimensionality of their *in vivo* counterparts are welcome.





Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed by the Science Citation Index Expanded (Web of Science) and BIOSIS Previews, Scopus and other databases. Citations available in PubMed, full-text archived in PubMed Central.

Rapid publication: manuscripts are peer-reviewed and a first decision provided to authors approximately 15.0 days after submission; acceptance to publication is undertaken in 4.0 days (median values for papers published in this journal in the second half of 2019).

Contact Us
